Biomark Diagnostics Inc. (CSE:BUX)

Canada flag Canada · Delayed Price · Currency is CAD
0.2500
0.00 (0.00%)
Apr 25, 2025, 9:40 AM EDT
-16.67%
Market Cap 22.18M
Revenue (ttm) 155.03K
Net Income (ttm) -1.90M
Shares Out n/a
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,000
Average Volume 10,228
Open 0.2500
Previous Close 0.2500
Day's Range 0.2500 - 0.2500
52-Week Range 0.1800 - 0.3050
Beta -0.52
RSI 51.25
Earnings Date Jul 25, 2025

About Biomark Diagnostics

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada. [Read more]

Sector Healthcare
Founded 2014
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol BUX
Full Company Profile

Financial Performance

In 2023, Biomark Diagnostics's revenue was 163,220, an increase of 6.34% compared to the previous year's 153,492. Losses were -1.43 million, -22.52% less than in 2022.

Financial Statements

News

There is no news available yet.